|Last Price||Today's Change||52-Week Range||Trading Volume|
|256.56||0.19 (+0.07%)||82.51 - 258.95||704.9 thousand (Below Avg)|
Market data as of 4:00PM 03/27/15. Quotes are delayed by at least 15 min.
Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
03/16/2015 3:00 PM ET